Rodman & Renshaw reiterated its Oncothyreon ONTY Market Outperform rating and $10 price target in a research report published today.
In the report, Rodman & Renshaw states, "We believe that the promising Phase 2 data for Stimuvax establishes the potential for success in two ongoing Phase 3 trials, with a potentially transformative interim analysis readout expected by 1Q12 that could generate substantial value for shareholders."
Shares of Oncothyreon closed today at $6.46, up 4.36% from Wednesday's market close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in